{"nctId":"NCT01429441","briefTitle":"Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole","startDateStruct":{"date":"2011-10"},"conditions":["Vitreomacular Adhesion Including Macular Hole"],"count":220,"armGroups":[{"label":"Ocriplasmin","type":"EXPERIMENTAL","interventionNames":["Drug: Ocriplasmin"]},{"label":"Sham injection","type":"SHAM_COMPARATOR","interventionNames":["Other: Sham injection"]}],"interventions":[{"name":"Ocriplasmin","otherNames":[]},{"name":"Sham injection","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects 18 years of age or older and of either gender\n* Presence of vitreomacular adhesion\n* Best corrected visual acuity (BCVA) of 20/32 or worse in study eye\n* BCVA of 20/800 or better in the non-study eye\n\nExclusion Criteria:\n\n* History or current evidence of proliferative retinopathy, exudative age-related macular degeneration (AMD) or retinal vein occlusion in the study eye\n* Any vitreous hemorrhage or any other vitreous opacification which precludes the visualization of the posterior pole by visual inspection OR adequate assessment of the macula by spectral-domain optical coherence tomography (SD-OCT) in the study eye\n* Macular hole of \\> 400 µm diameter in the study eye\n* Presence of epiretinal membrane (ERM)\n* Aphakia in the study eye\n* High myopia (more than 8D) in study eye\n* History of rhegmatogenous retinal detachment in either eye\n* History of vitrectomy in the study eye\n* Previous participation in this trial or prior administration of ocriplasmin in the study eye","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Subjects With Pharmacological Vitreomacular Adhesion (VMA) / (Vitreomacular Traction [VMT]) Resolution at Day 28","description":"Pharmacological VMA resolution without anatomical defect, based on SD-OCT and determined by the masked central reading center (CRC), with post-resolution vitrectomy considered as a failure. Missing data were imputed using the last observation carried forward (LOCF) method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.7","spread":null},{"groupId":"OG001","value":"6.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects With a ≥2 Lines Improvement in Best-corrected Visual Acuity (BCVA) From Baseline at Month 24","description":"≥2 lines improvement in BCVA from baseline, irrespective of vitrectomy. Missing data were imputed using the LOCF method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.5","spread":null},{"groupId":"OG001","value":"39.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":49,"n":146},"commonTop":["Vitreous floaters","Color vision tests abnormal","Photopsia","Ophthalmological examination abnormal","Visual acuity reduced"]}}}